StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38+0.00 (0.00%)

Close on Nov 18, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics market cap

Market capitalization is the share price multiplied by the number of shares outstanding.

Inhibikase Therapeutics's market cap was $215.21M on Nov 11, 2026, against $113.71M a year earlier. Over the last 5 years it ranged from $4.69M to $305.00M, with a median of $23.10M.

Market Cap at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$215.21M+40.3%
2025Dec 31, 2025$153.36M+532.2%
2024Dec 31, 2024$24.26M+256.3%
2023Dec 29, 2023$6.81M-46.0%
2022Dec 30, 2022$12.61M-65.9%
2021Dec 31, 2021$36.95M–

More Inhibikase Therapeutics figures

See a number that looks wrong?